WO2024141977 - ENGINEERED NATURAL KILLER CELLS AND RELATED METHODS
National phase entry:
Publication Number
WO/2024/141977
Publication Date
04.07.2024
International Application No.
PCT/IB2023/063330
International Filing Date
28.12.2023
Title **
[English]
ENGINEERED NATURAL KILLER CELLS AND RELATED METHODS
[French]
CELLULES TUEUSES NATURELLES MODIFIÉES ET PROCÉDÉS ASSOCIÉS
Applicants **
ASTELLAS PHARMA INC.
Inventors
CLARY, Kim
RUSSELL, David
WADA, Yusuke
HALL, Matthew
ITO, Masayuki
BELAY, Eyayu
DAVIS, Ryan
GRIMLEY, Joshua
BOURSALIAN, Tamar
GOO, Hyun Jung
Priority Data
63/477,785
29.12.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3577 | |
| EPO | Filing, Examination, Granting | 33942 | |
| Japan | Filing, Examination, Granting | 3390 | |
| South Korea | Filing, Examination, Granting | 4587 | |
| USA | Filing, Examination, Granting | 13540 |
Total:
59,036
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The disclosure provides a population of engineered natural killer cells, wherein the NK cells express at least one polypeptide selected from the group consisting of human leukocyte antigen E, human leukocyte antigen F, and human leukocyte antigen G. The NK cells comprise a genetically engineered disruption of one or more copies of endogenous β-2 microglobulin and a genetically engineered disruption of one or more copies of a human leukocyte antigen class Il-related gene selected from the group consisting of regulatory factor X associated ankyrin containing protein, regulatory factor 5, regulatory factor X associated protein, and class II transactivator. A method of producing human pluripotent stem cell-derived engineered natural killer cells under feeder free conditions also is provided, as is a method of treating a disease or disorder in a subject by administering the NK cells to the subject.[French]
La présente invention concerne une population de cellules tueuses naturelles modifiées, les cellules NK exprimant au moins un polypeptide choisi dans le groupe constitué de l'antigène leucocytaire humain E, de l'antigène leucocytaire humain F et de l'antigène leucocytaire humain G. Les cellules NK comprennent une perturbation par génie génétique d'une ou plusieurs copies de la β-2 microglobuline endogène et une perturbation par génie génétique d'une ou plusieurs copies d'un gène lié à l'antigène leucocytaire humain de classe Il choisi dans le groupe constitué de la protéine contenant de l'ankyrine associée au facteur de régulation X, du facteur de régulation 5, de la protéine associée au facteur de régulation X et du transactivateur de classe II. La présente invention concerne également un procédé de production de cellules tueuses naturelles issues de cellules souches pluripotentes humaines dans des conditions exemptes de nourricières, ainsi qu'un procédé de traitement d'une maladie ou d'un trouble chez un sujet par l'administration des cellules NK au sujet.